Will Biocon go the Sun Pharma way Hive-off its subsidiaries into separate entities and list them on the bourses The answer according to Biocon Chief Kiran Majumdar Shaw is a emphatic yes.Syngene and Clinigene are often referred as pioneers of the Indian custom and clinical services industry, now Biocon may be looking at listing them at the right time to unlock value.Biocon may also list itself on the international bourses in its effort to strengthen its pharmaceutical business and in all probability it is going to be the US market.
Kiran Majumdar Shaw says that US is a natural fit for the listing as it is a market, which fully knows how to value research driven pharmaceutical businesses.Biocon is also scouting for acquisitions; soon the company will have over $100 million in its kitty from the sale of its enzymes business. The company may utilise its internal resources and if the need be look at raising more money. Though rupee continues to be a worry for Biocon, it is learning to live with that fact and as always the company is positive on its research capabilities for some time.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment